What is HC Wainwright’s Forecast for MLTX Q1 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

Several other research firms also recently weighed in on MLTX. The Goldman Sachs Group lowered their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday. Needham & Company LLC boosted their price target on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, MoonLake Immunotherapeutics presently has an average rating of “Buy” and an average target price of $83.20.

MoonLake Immunotherapeutics Stock Down 1.4 %

MoonLake Immunotherapeutics stock opened at $41.77 on Friday. The company has a market capitalization of $2.67 billion, a PE ratio of -32.38 and a beta of 1.28. The firm has a fifty day simple moving average of $46.90 and a two-hundred day simple moving average of $48.99. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at about $1,091,000. Jefferies Financial Group Inc. purchased a new position in shares of MoonLake Immunotherapeutics during the fourth quarter valued at about $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock valued at $2,287,000 after buying an additional 6,422 shares during the period. Woodline Partners LP increased its position in shares of MoonLake Immunotherapeutics by 26.3% during the fourth quarter. Woodline Partners LP now owns 293,535 shares of the company’s stock valued at $15,895,000 after buying an additional 61,105 shares during the period. Finally, Wexford Capital LP increased its position in shares of MoonLake Immunotherapeutics by 71.4% during the fourth quarter. Wexford Capital LP now owns 24,000 shares of the company’s stock valued at $1,300,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.